Targeted therapy of ovarian cancer including immune check point inhibitor.
Targeted therapy of ovarian cancer including immune check point inhibitor.
复制标题
DOI：
10.3904/kjim.2017.008
复制
发表时间：
2017-09
期刊：
影响因子：
--
通讯作者：
Song HS
中科院分区：
文献类型：
--
作者：
Kim JY;Cho CH;Song HS
上皮性卵巢癌是女性癌症相关死亡的第八大常见原因，因为大多数患者在诊断时患有晚期疾病。尽管细胞减灭术和铂类化疗仍然是治疗的金标准，但卵巢癌的复发率仍然很高。试图通过添加第三种细胞毒性药物来改善这种标准的双药化疗，但未能影响无进展生存期或总生存期，并导致毒副作用增加。一些抗血管生成剂，聚（ADP-核糖）聚合酶和免疫检查点抑制剂已在上皮性卵巢癌治疗的早期阶段显示出疗效。如最近的临床试验所示，单独使用贝伐单抗、西地尼布、帕唑帕尼、奥拉帕尼和鲁卡帕尼或与常规细胞毒性药物联合使用，可改善无进展生存期。免疫检查点抑制剂（如nivolumab）的试验显示，在一小部分卵巢癌病例中的反应延长，但需要进一步探索。在这篇综述中，我们讨论了靶向治疗对卵巢癌的作用，包括使用免疫检查点抑制剂。
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects. Some anti-angiogenic agents, poly(ADP-ribose) polymerase, and immune checkpoint inhibitors have shown efficacy in early stages of development for the treatment of epithelial ovarian cancer. As demonstrated in recent clinical trials, the use of bevacizumab, cediranib, pazopanib, olaparib, and rucaparib, either alone or in combination with conventional cytotoxic agents, improves progression-free survival. Trials on immune checkpoint inhibitors such as nivolumab have revealed prolonged responses in a small set of ovarian cancer cases but require further exploration. In this review, we discuss the role of targeted therapies against ovarian cancer, including the use of immune checkpoint inhibitors.
登录
查看更多内容
影响因子：
1.8
作者：
Lokadasan R;James FV;Narayanan G;Prabhakaran PK
通讯作者：
Prabhakaran PK
影响因子：
45.3
作者：
MARKMAN, M;ROTHMAN, R;LEWIS, JL
通讯作者：
LEWIS, JL
影响因子：
45.3
作者：
du Bois, A;Weber, B;Pujade-Lauraine, E
通讯作者：
Pujade-Lauraine, E
影响因子：
45.3
作者：
Matulonis, Ursula A.;Berlin, Suzanne;Penson, Richard T.
通讯作者：
Penson, Richard T.
DOI：
10.1186/s40661-016-0024-7
发表时间：
2016
期刊：
Gynecologic oncology research and practice
影响因子：
--
作者：
Meehan RS;Chen AP
通讯作者：
Chen AP